Application of combination of curcumin and aspirin in preparation of medicine for preventing polyp recurrence

Abstract

According to the application of curcumin combined with aspirin in preparation of the medicine for preventing polyp relapse, polyp is colorectal polyp and endometrial polyp, the combination of curcumin and aspirin in required treatment amount has a synergistic effect in preparation of the medicine for preventing polyp relapse, and the two medicines are combined for use to enhance the curative effect and reduce the side effect; the traditional Chinese medicine composition provides a new thought for preventing polyp relapse, and has important significance and wide application prospects. Tests prove that the combined use of curcumin and aspirin can effectively improve the postoperative clinical symptoms of colorectal polyp patients and effectively reduce the recurrence rate of the colorectal polyp patients. The curcumin and the aspirin are combined for use, so that a good effect is achieved on a patient after endometrial polyp resection, the endometrial thickness of the patient can be reduced, the clinical curative effect can be improved, and disease recurrence is avoided.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to application of curcumin combined with aspirin in preparing a drug for preventing polyp recurrence. Background Art

[0002] Aspirin is a non-steroidal anti-inflammatory drug that is widely used in clinical practice in the treatment of cardiovascular system, cervical tumors, and pulmonary hypertension.

[0003] Curcumin is an active ingredient extracted from turmeric. As a natural pigment and traditional Chinese medicine ingredient, curcumin has many pharmacological effects, including anti-inflammatory, lipid-lowering, antibacterial, antioxidant and oxygen free radical scavenging effects.

[0004] Intestinal polyps refer to raised lesions protruding from the surface of the colon mucosa into the intestinal cavity. Before the pathological nature is determined, they are collectively called polyps. Colorectal polyps account for 80% of them. They are single or multiple, more common in men than in women, and the incidence is positively correlated with age. In recent years, with the popularization of colonoscopy and changes in people's lifestyles, the detection rate of intestinal polyps in my country has increased year by year. The recovery of intestinal function after resection of this disease and the prevention of intestinal polyp recurrence have become the focus of current research. Intestinal polyps are believed to be caused by the combined influence of multiple factors such as improper diet, excessive fatigue, emotional disorders, and physical weakness after illness, which lead to visceral disorders in patients. Treatment is advocated to clear away heat and strengthen the spleen, regulate qi and remove dampness, and invigorate qi and promote blood circulation.

[0005] Endometrial polyps are gynecological diseases with a high incidence rate. Clinical treatment mainly relies on surgical intervention. Among them, the more common treatment procedure is hysteroscopic endometrial polypectomy, which has a certain therapeutic effect and effectively improves the patient's clinical symptoms, but there is a high recurrence rate in patients after surgery. Therefore, the clinical response to the recurrence of postoperative diseases has attracted great attention. Traditional Chinese medicine classifies endometrial polyps into the categories of "infertility", "prolonged menstruation", "metrorrhagia" and "menorrhagia". It is believed that factors such as insufficient qi, excessive fatigue, insufficient qi and blood, and weak constitution of patients are the main causes of the disease, or due to liver qi stagnation, blood circulation is blocked, causing stasis in the uterus. Therefore, when clinically intervening in patients undergoing hysteroscopic endometrial polypectomy, dispersing knots and removing blood stasis, and removing blood stasis and activating blood circulation should be the main ideas.

[0006] So far, curcumin combined with aspirin has not been used in preventing polyp recurrence. Summary of the invention

[0007] In view of this, the present invention proposes the use of curcumin combined with aspirin in the preparation of a drug for preventing the recurrence of polyps.

[0008] The technical solution of the present invention is achieved in this way:

[0009] Application of curcumin combined with aspirin in the preparation of drugs for preventing polyp recurrence.

[0010] Furthermore, the polyps are colorectal polyps and endometrial polyps.

[0011] Furthermore, the curcumin includes curcumin and pharmaceutically acceptable salts.

[0012] Furthermore, the aspirin includes aspirin and pharmaceutically acceptable salts.

[0013] Furthermore, the mass ratio of curcumin to aspirin in the drug for preventing polyp recurrence is 5-10:1-20.

[0014] Furthermore, the mass ratio of curcumin to aspirin in the drug for preventing polyp recurrence is 5:1, 5:10, 5:20, 8:1, 8:10, 8:20, 10:1, 10:10 or 10:20.

[0015] Furthermore, the mass ratio of curcumin to aspirin in the drug for preventing polyp recurrence is 5:1, 8:10 or 10:20.

[0016] Furthermore, the drug for preventing polyp recurrence includes a preparation made of curcumin and aspirin and a pharmaceutically acceptable carrier thereof.

[0017] Furthermore, the preparation is an oral preparation, including: tablets, pills, decoctions, granules, capsules, controlled-release or sustained-release preparations.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] The combination of curcumin and aspirin in the amount required for treatment has a synergistic effect in the preparation of a drug for preventing the recurrence of polyps. The combined use of the two drugs can reduce the dosage of aspirin and reduce the adverse reactions of aspirin. The combined use of the two drugs enhances the therapeutic effect and reduces the side effects, which is greater than the effect of using the two drugs alone. It provides a new idea for preventing the recurrence of polyps and has important significance and broad application prospects.

[0020] Experimental verification shows that the combined use of curcumin and aspirin can effectively improve the clinical symptoms of patients with colorectal polyps after surgery and effectively reduce the recurrence rate of colorectal polyps. The combined use of curcumin and aspirin has a good effect on patients after endometrial polypectomy, not only reducing the thickness of the patient's endometrium, but also improving the clinical efficacy and avoiding disease recurrence. DETAILED DESCRIPTION

[0021] In order to better understand the technical content of the present invention, specific embodiments are provided below to further illustrate the present invention.

[0022] Unless otherwise specified, the experimental methods used in the embodiments of the present invention are all conventional methods.

[0023] Unless otherwise specified, the materials, reagents, etc. used in the embodiments of the present invention can be obtained from commercial sources.

[0024] Example 1

[0025] 1. Clinical data

[0026] The subjects of this study were 200 patients who had undergone colorectal polyps surgery, aged 25 to 65 years old, 100 males and 100 females, all of whom were treated in the hospital's specialist clinics and general clinics. They were diagnosed with colorectal polyps by colonoscopy and underwent surgical treatment.

[0027] The patients were randomly divided into treatment group and control group 1-3 groups according to the order of their visits, with 50 patients in each group. There was no significant difference in gender, age and clinical symptoms among the patients in each group (P>0.05), and the patients were comparable.

[0028] 2. Inclusion and Exclusion Criteria

[0029] Inclusion criteria: All included patients were diagnosed with colorectal polyps and underwent surgical resection by colonoscopy due to various abdominal symptoms such as abdominal distension and pain, diarrhea, constipation, abdominal discomfort, etc., and there were no abnormalities in the three routine tests of blood, urine, and feces, fecal bacterial culture, blood sugar, liver function, kidney function, and abdominal B-ultrasound. Patients voluntarily participated in this study and signed the informed consent form.

[0030] Exclusion criteria: severe organ disorders such as heart, liver, and kidney, malignant blood system diseases, mental disorders, contraindications to the drugs used, and unwillingness to participate in this study.

[0031] 3. Methods

[0032] 3.1 Treatment groups

[0033] Patients who underwent colorectal polyp surgery were given routine fluid replacement and symptomatic treatment after surgery. After fasting for 1-2 days, they were given a combination of curcumin and aspirin. 8g of curcumin and 10g of aspirin were decocted and taken orally. The decoction was about 200ml. 100ml was taken twice a day, 1 hour after meals. One month was considered as one course of treatment, and three courses of treatment were continued. Colonoscopy was performed 6 and 12 months after surgery.

[0034] 3.2 Control group

[0035] Control group 1: Patients who underwent colorectal polyp resection were given routine fluid replacement and symptomatic treatment after surgery. After fasting for 1-2 days, they were given curcumin alone. 8g of curcumin was decocted and taken to obtain about 200ml of liquid. 100ml was taken twice a day, 1 hour after meals, in the morning and evening.

[0036] Control group 2: Patients who underwent colorectal polyp resection were given routine fluid replacement and symptomatic treatment after surgery. After fasting for 1-2 days, aspirin was given alone. 10g of aspirin was decocted and taken to obtain about 200ml of liquid. 100ml was taken twice a day, 1 hour after meals, in the morning and evening.

[0037] Control group 3: Patients who underwent colorectal polyp resection were given routine fluid replacement and symptomatic treatment after surgery. After fasting for 1-2 days, they were given a combination of Bifidobacterium and Lactobacillus live bacteria tablets, orally, 2 g / time, 3 times / day.

[0038] The control group was treated for 3 consecutive courses, with one month as one course of treatment. Colonoscopy was performed 6 and 12 months after surgery.

[0039] 4. Criteria for determining efficacy

[0040] The criteria for the diagnosis and efficacy of TCM syndromes were used to formulate the criteria. Recurrence was defined as the discovery of colorectal polyps after a colonoscopy was performed again after the patient underwent endoscopic resection of colorectal polyps and confirmed that all polyps had been removed during the last polypectomy. The efficacy of TCM syndromes was based on the Guiding Principles for Clinical Research of New Chinese Medicines.

[0041] Scoring was performed based on the severity of the patient's main symptoms and signs: none, mild, moderate, and severe, with 0, 2, 4, and 6 points respectively. The quantitative grading of TCM syndromes is shown in Table 1.

[0042] Table 1

[0043]

[0044]

[0045] Efficacy criteria:

[0046] Recovery: symptoms and signs disappear or almost disappear, and syndrome score decreases by more than 95%;

[0047] Markedly effective: symptoms and signs are significantly improved, and the syndrome score is reduced by >70%;

[0048] Effective: symptoms and signs are improved, and the syndrome score is reduced by >30%;

[0049] Ineffective: There is no significant improvement in symptoms and signs, and the clinical manifestations may even worsen, with the syndrome score decreasing by less than 30%.

[0050] The formula for calculating the syndrome score is: (score before treatment - score after treatment) / score before treatment × 100%

[0051] The results are shown in Table 2.

[0052] Table 2

[0053] Group Number of cases / case Recovered / case Significantly effective / case Valid / Example Invalid / Example Total effective rate / % Treatment Group 50 15 18 15 2 96 Control group 1 50 7 11 15 17 66 Control group 2 50 8 10 13 19 62 Control group 3 50 4 8 18 22 56

[0054] Colonoscopy was performed again at 6 and 12 months, and the recurrence rate is shown in Table 3.

[0055] Table 3

[0056]

[0057] As can be seen from Table 2, the curcumin and aspirin combination of the present invention has a greater therapeutic effect than the single medication, and is also better than traditional postoperative intervention, with a total effective rate of 96%. As can be seen from Table 3, the curcumin and aspirin combination of the present invention can avoid the occurrence of adverse postoperative complications and effectively reduce the recurrence rate of polyps. Therefore, the combined application of curcumin and aspirin in the treatment of postoperative patients with colorectal polyps has obvious clinical efficacy, can accelerate the patient's recovery process, and reduce the risk of recurrence of colorectal polyps.

[0058] Example 2

[0059] 1. Clinical data

[0060] The subjects of this study were 200 patients with blood stasis syndrome who received hysteroscopic endometrial polypectomy in our hospital, aged 25 to 45 years old. They were randomly divided into treatment group and control group 1-3 groups according to the order of their visit, with 50 people in each group. There was no significant difference in age and clinical symptoms among each group of patients (P>0.05), and the patients were comparable.

[0061] 2. Inclusion and Exclusion Criteria

[0062] Inclusion criteria: no fertility needs within six months, informed consent from the patient and family, receiving hysteroscopic endometrial polypectomy in this hospital, and confirmed to be endometrial polyps after postoperative pathological examination;

[0063] Exclusion criteria: patients with contraindications to the use of progestins, such as progestin-dependent tumors, sex hormone-related malignant tumors, patients with concurrent psychiatric diseases, patients with allergic reactions to the study drugs, patients with severe liver or kidney function damage; patients who dropped out of the study due to patient reasons.

[0064] 3. Methods

[0065] 3.1 Treatment groups

[0066] Patients who underwent hysteroscopic endometrial polypectomy were given symptomatic treatment after surgery, and were given a combination of curcumin and aspirin. 8g of curcumin and 10g of aspirin were decocted and taken, and the decoction was about 200ml. 100ml was taken twice a day, 1 hour after meals, in the morning and evening. The starting time for taking the drug was the first day of the menstrual period, and 5 consecutive days of treatment was a course of treatment, for a total of 3 courses.

[0067] 3.2 Control group

[0068] Control group 1: Patients who underwent hysteroscopic endometrial polypectomy received symptomatic treatment after surgery and were given curcumin alone. 8g of curcumin was decocted and taken orally. The decoction was about 200ml and 100ml was taken twice a day, 1 hour after meals, in the morning and evening.

[0069] Control group 2: Patients who underwent hysteroscopic endometrial polypectomy received symptomatic treatment after surgery and were given aspirin alone. 10g of aspirin was decocted and taken to obtain about 200ml of liquid, 100ml of which was taken twice a day, 1 hour after meals, in the morning and evening.

[0070] Control group 3: Patients who underwent hysteroscopic endometrial polypectomy received postoperative symptomatic treatment and were given dydrogesterone, oral administration, 10 mg / time, twice / day;

[0071] The starting time for taking the drug in the above control group was the first day of the menstrual period, and 5 days of continuous treatment was considered a course of treatment, with a total of 3 courses of treatment.

[0072] 4. Criteria for determining efficacy

[0073] 4.1 Comparison of endometrial thickness among groups

[0074] Before treatment and in the mid-luteal phase after 3 courses of treatment, patients underwent transvaginal ultrasound examination to measure the endometrial thickness.

[0075] 4.2 Comparison of treatment effects among groups

[0076] Criteria for judging efficacy:

[0077] Ineffective: clinical symptoms are not relieved, and the reduction rate of endometrial thickness is <10%;

[0078] Effective: Clinical symptoms improved, and the endometrial thickness decreased by 10%-20%;

[0079] Markedly effective: clinical symptoms basically disappear, and the reduction rate of endometrial thickness is ≥30%;

[0080] Total effective rate = (number of markedly effective cases + number of effective cases) / total number of cases × 100%.

[0081] 4.3 Comparison of recurrence rates among groups

[0082] 3-7 days after the end of menstruation at 3 and 6 months of treatment, the patients will undergo gynecological hysteroscopy or color Doppler ultrasound examination;

[0083] Recurrence criteria: Hysteroscopy reveals endometrial polyps, color Doppler ultrasound reveals endometrial thickening and uneven echoes, and endometrial sonogram shows a high-echo mass in the uterine cavity. If both hysteroscopy and color Doppler ultrasound results show no abnormalities in the uterine cavity, then there is no recurrence.

[0084] 5. Results

[0085] 5.1 The results of endometrial thickness in each group are shown in Table 4.

[0086] Table 4

[0087] Group Number of cases / case Before surgery / mm Postoperative treatment 3 months / mm Postoperative treatment 6 months / mm Treatment Group 50 12.32±1.24 8.04±1.18 7.01±1.19 Control group 1 50 12.31±1.26 9.48±1.26 8.24±1.27 Control group 2 50 12.33±1.22 9.35±1.24 8.28±1.25 Control group 3 50 12.30±1.13 9.93±1.27 8.47±1.34

[0088] As can be seen from Table 4, the endometrial thickness of the curcumin combined with aspirin treatment group after 3 and 6 months of treatment was thinner than that of the control group 1-2 treated with the single drug.

[0089] 5.2 The treatment effect results of each group are shown in Table 5.

[0090] Table 5

[0091] Group Number of cases / case Significantly effective / case Valid / Example Invalid / Example Total Effectiveness Treatment Group 50 25 23 2 96％ Control group 1 50 10 32 8 84％ Control group 2 50 8 32 10 80％ Control group 3 50 5 25 20 60％

[0092] As can be seen from Table 5, the total effective rate of the curcumin combined with aspirin treatment group of the present invention is greater than the total effective rate of the control group 1-2 using the single medication, and is also greater than the total effective rate of the traditional intervention.

[0093] 5.2 The recurrence rate results of each group are shown in Table 6.

[0094] Table 6

[0095] Group Number of cases / case 3 months postoperative treatment 6 months postoperative treatment Treatment Group 50 2％ 4％ Control group 1 50 6％ 12％ Control group 2 50 6％ 12％ Control group 3 50 8％ 16％

[0096] As can be seen from Table 6, the relapse rate of the curcumin combined with aspirin treatment group of the present invention at 3 and 6 months of treatment was lower than the relapse rate of the control group 1-2 of single medication, and was also lower than the relapse rate of traditional intervention.

[0097] In summary, the combined use of curcumin and aspirin in patients after hysteroscopic endometrial polypectomy can achieve good results. It can not only reduce the thickness of the patients' endometrium, but also improve the clinical efficacy and avoid disease recurrence. It is worthy of clinical promotion.

[0098] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Application of curcumin combined with aspirin in the preparation of drugs for preventing recurrence of polyps.

2. The use according to claim 1, characterized in that The polyps are colorectal polyps and endometrial polyps.

3. The use according to claim 1, characterized in that The curcumin includes curcumin and pharmaceutically acceptable salts.

4. The use according to claim 1, characterized in that The aspirin includes aspirin and pharmaceutically acceptable salts.

5. The use according to claim 1, characterized in that The mass ratio of curcumin to aspirin in the drug for preventing polyp recurrence is 5-10:1-20.

6. The use according to claim 5, characterized in that The mass ratio of curcumin to aspirin in the drug for preventing polyp recurrence is 5:1, 5:10, 5:20, 8:1, 8:10, 8:20, 10:1, 10:10 or 10:

20.

7. The use according to claim 6, characterized in that The mass ratio of curcumin to aspirin in the drug for preventing polyp recurrence is 5:1, 8:10 or 10:

20.

8. The use according to claim 1, characterized in that The drug for preventing polyp recurrence comprises a preparation made of curcumin, aspirin and pharmaceutically acceptable carriers thereof.

9. The use according to claim 8, characterized in that The preparation is an oral preparation, including: tablets, pills, decoctions, granules, capsules, controlled-release or sustained-release preparations.

Images